NO2385374T3 - - Google Patents

Info

Publication number
NO2385374T3
NO2385374T3 NO10162066A NO10162066A NO2385374T3 NO 2385374 T3 NO2385374 T3 NO 2385374T3 NO 10162066 A NO10162066 A NO 10162066A NO 10162066 A NO10162066 A NO 10162066A NO 2385374 T3 NO2385374 T3 NO 2385374T3
Authority
NO
Norway
Application number
NO10162066A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42315849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2385374(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2385374T3 publication Critical patent/NO2385374T3/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO10162066A 2010-05-05 2010-05-05 NO2385374T3 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10162066.4A EP2385374B2 (en) 2010-05-05 2010-05-05 Lipidomic biomarkers for atherosclerosis and cardiovascular disease

Publications (1)

Publication Number Publication Date
NO2385374T3 true NO2385374T3 (cg-RX-API-DMAC10.html) 2014-06-07

Family

ID=42315849

Family Applications (2)

Application Number Title Priority Date Filing Date
NO10162066A NO2385374T3 (cg-RX-API-DMAC10.html) 2010-05-05 2010-05-05
NO11719802A NO2567240T3 (cg-RX-API-DMAC10.html) 2010-05-05 2011-05-05

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO11719802A NO2567240T3 (cg-RX-API-DMAC10.html) 2010-05-05 2011-05-05

Country Status (9)

Country Link
US (6) US9046538B2 (cg-RX-API-DMAC10.html)
EP (3) EP2385374B2 (cg-RX-API-DMAC10.html)
JP (1) JP5871244B2 (cg-RX-API-DMAC10.html)
CN (1) CN102971633B (cg-RX-API-DMAC10.html)
CA (1) CA2798238C (cg-RX-API-DMAC10.html)
DK (2) DK2385374T4 (cg-RX-API-DMAC10.html)
ES (2) ES2455124T5 (cg-RX-API-DMAC10.html)
NO (2) NO2385374T3 (cg-RX-API-DMAC10.html)
WO (1) WO2011138419A1 (cg-RX-API-DMAC10.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9046540B2 (en) * 2008-09-29 2015-06-02 Plaxgen Inc. Assay, composition and non-enzymatic mechanism of statin in modulating lipid metabolism
US9110086B2 (en) 2009-11-27 2015-08-18 Baker Idi Heart And Diabetes Institute Holdings Limited Lipid biomarkers for stable and unstable heart disease
US9285378B2 (en) 2010-01-29 2016-03-15 Metanomics Gmbh Means and methods for diagnosing heart failure in a subject
ES2455124T5 (es) 2010-05-05 2018-05-08 Zora Biosciences Oy Biomarcadores lipidómicos para la aterosclerosis y afección cardíaca
CN103154742B (zh) * 2010-06-20 2017-11-21 佐拉生物科学公司 用于鉴定高风险冠状动脉疾病患者的脂质组学标志
US8765479B1 (en) * 2011-03-13 2014-07-01 Atherotech, Inc. Methods for determining the risk of coronary heart disease and clinical manifestations of coronary heart disease
US9541565B2 (en) 2011-04-08 2017-01-10 Zora Biosciences Oy Biomarkers for sensitive detection of statin-induced muscle toxicity
EP2592423A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
EP2592422A1 (en) * 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
EP2642295A1 (en) * 2012-03-22 2013-09-25 Nestec S.A. 1-O-alkyl-2-acylglycerophosphocholine (PC-O) 40:1 as biomarker for healthy ageing
EP2642293A1 (en) 2012-03-22 2013-09-25 Nestec S.A. 9-oxo-octadecadienoic acid (9-oxo-HODE)as as biomarker for healthy ageing
EP2667197B1 (en) * 2012-05-25 2015-09-16 Zora Biosciences OY Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
CN103149312B (zh) * 2013-02-05 2015-02-04 东北农业大学 一种利用超高效液相色谱串联四级杆质谱分析婴儿乳粉中唾液酸的方法
EP2778686B1 (en) * 2013-03-13 2016-07-27 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Lipidomics of familial longevity
WO2015071145A1 (en) * 2013-11-14 2015-05-21 Nestec S.A. Lipid biomarkers of healthy ageing
KR101660328B1 (ko) 2014-01-14 2016-09-27 한국과학기술연구원 심혈관 질환 진단용 바이오 마커
BR112016023418A8 (pt) 2014-04-10 2019-12-10 MEP Equine Solutions LLC método e kit para a quantificação de ovos de parasitas nas fezes
US9347960B2 (en) 2014-06-16 2016-05-24 Zora Biosciences, Oy Ceramides and their use in diagnosing CVD
CN107110939B (zh) * 2014-09-11 2021-05-14 力保科学公司 用于测定心血管疾病或事件的风险参数的系统
WO2016100549A2 (en) * 2014-12-16 2016-06-23 Washington University Ceramides for evaluating risk of cardiovascular disease
HUE047951T2 (hu) 2015-01-09 2020-05-28 Global Genomics Group Llc Vér alapú biomarkerek atheroszklerotikus koszorúsér betegség diagnosztizálására
EP3121599A1 (en) * 2015-07-23 2017-01-25 Medizinische Hochschule Hannover Analysis for atherosclerosis
WO2017029401A1 (en) * 2015-08-19 2017-02-23 Metanomics Gmbh Means and methods for diagnosing cardiac disease in a subject
CN108027354B (zh) * 2015-08-20 2021-01-08 深圳华大生命科学研究院 冠心病的生物标志物
US10184932B2 (en) 2015-12-07 2019-01-22 Zora Biosciences Oy Use of ceramides and LPLs in diagnosing CVD
CN105486778B (zh) * 2016-01-25 2017-11-03 齐炼文 诊断区分稳定型心绞痛和急性冠脉综合征的代谢标志物
CN105445408B (zh) * 2016-01-25 2018-06-12 齐炼文 诊断区分冠状动脉粥样硬化和稳定型心绞痛的代谢标志物
CN108872404A (zh) * 2017-05-09 2018-11-23 中国科学院上海生命科学研究院 超长链饱和脂肪酸或其检测试剂在代谢综合征患病风险预测中的应用
CN107144624B (zh) * 2017-05-15 2021-01-05 中国科学院生态环境研究中心 甄别二氧化硅颗粒来源的方法
TWI835735B (zh) * 2017-06-12 2024-03-21 比利時商健生藥品公司 減少或預防第ii型糖尿病患者中心血管事件之方法
CN109870536B (zh) * 2017-12-05 2021-08-10 中国科学院大连化学物理研究所 一种基于液相色谱-质谱联用的高覆盖脂质组学分析方法
CN114062581A (zh) * 2017-12-14 2022-02-18 江苏豪思生物科技有限公司 一种用于评估冠状动脉疾病的试剂盒
WO2019119049A1 (en) * 2017-12-20 2019-06-27 Baker Heart and Diabetes Institute Method of predicting drug therapeutic responder status and methods of treatment
CN110433282B (zh) * 2018-05-04 2023-03-14 上海交通大学医学院附属瑞金医院 胰高血糖素样肽-1在制备治疗钙化性主动脉瓣疾病药物方面的应用
WO2020115288A1 (en) 2018-12-06 2020-06-11 Zora Biosciences Oy Biomarkers for cardiovascular events
US20220214367A1 (en) * 2019-04-15 2022-07-07 Board Of Regents, The University Of Texas System Calibration methods and compositions for biomolecule analysis
WO2020242796A1 (en) * 2019-05-28 2020-12-03 Ohio University Assays and methods for screening for cardiovascular disease using ldl subclasses and endothelial nitric oxide/peroxynitrite balance
CN112305122B (zh) * 2020-10-30 2021-07-13 河北医科大学第二医院 代谢物标志物及其在疾病中的应用
CN112147344B (zh) * 2020-10-30 2021-07-13 河北医科大学第二医院 动脉粥样硬化性脑梗死的代谢标志物及其在诊疗中的应用
CN112305119B (zh) * 2020-10-30 2021-08-17 河北医科大学第二医院 动脉粥样硬化性脑梗死的生物标志物及其应用
CN112305124B (zh) * 2020-10-30 2022-03-04 河北医科大学第二医院 一种生物标志物及其在疾病诊断中的应用
CN113782177A (zh) * 2020-12-02 2021-12-10 北京市心肺血管疾病研究所 一种用于鉴别诊断冠心病患者斑块稳定性的数据处理装置、系统
CN112630330B (zh) * 2020-12-08 2021-12-21 河北医科大学第二医院 小分子物质在脑梗死诊断中的应用
JP2024517653A (ja) * 2021-04-21 2024-04-23 アルベルト・アインシュタイン・カレッジ・オブ・メディシン 神経細胞プロテオームを崩壊に対して安定化して血管細胞を保護する方法
CN113295793B (zh) * 2021-05-20 2022-11-04 复旦大学附属中山医院 预测早期糖尿病以及糖尿病发生的生物标志物、其检测方法与应用
CN116087486B (zh) * 2021-11-08 2024-02-02 中国医学科学院阜外医院 糖尿病患者早期预测心血管疾病（cvd）的生物标志物及其用途
CN113960222B (zh) * 2021-12-23 2022-02-25 中国中医科学院医学实验中心 基于血清样本的胆汁酸全通路代谢轮廓的检测方法及其应用
CN113960221B (zh) * 2021-12-23 2022-02-25 中国中医科学院医学实验中心 基于粪便样本的胆汁酸全通路代谢轮廓的检测方法及其应用
CN114791459B (zh) * 2022-03-29 2023-02-14 浙江苏可安药业有限公司 用于检测肺结核的血清代谢标志物及其试剂盒
CN116973427A (zh) * 2022-04-21 2023-10-31 岛津企业管理（中国）有限公司 用于动脉粥样硬化诊断的生物标志物及其应用
CN114705873B (zh) * 2022-06-06 2022-08-26 首都医科大学宣武医院 脂质作为颈动脉粥样硬化斑块诊断标志物的用途
CN115267214A (zh) * 2022-08-10 2022-11-01 南方医科大学珠江医院 一种脂质代谢标志物、其筛选方法及其在颅内动脉瘤中的应用
WO2024192471A1 (en) * 2023-03-20 2024-09-26 Baker Heart and Diabetes Institute Methods of assessing metabolic health
CN118258931B (zh) * 2024-05-29 2024-08-16 山东第一医科大学附属省立医院(山东省立医院) 用于预警女性动脉粥样硬化的代谢标志物组合及检测试剂盒

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210976B1 (en) * 1997-06-10 2001-04-03 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
AU5610801A (en) 2000-03-03 2001-09-12 Gerd Schmitz Method for the analysis of exogenic and endogenic cell activation based on measuring the aggregation of receptors
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
DK1353666T3 (da) 2001-01-02 2013-10-14 Cleveland Clinic Foundation Myeloperoxidase, en risikoindikator for cardiovasculær sygdom
JP4062514B2 (ja) * 2001-01-02 2008-03-19 ザ・クリーブランド・クリニック・ファンデーション ミエロペルオキシダーゼ、心臓血管疾患についての危険性指示因子
WO2003005628A2 (en) * 2001-07-06 2003-01-16 Lipomics Technologies, Inc. Generating, viewing, interpreting, and utilizing a quantitative database of metabolites
EP1520252B1 (en) 2002-06-28 2009-12-02 Nxp B.V. Data carrier with detection means for detecting a change made of information stored with storing means
WO2004038381A2 (en) 2002-10-25 2004-05-06 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US20070148779A1 (en) * 2003-03-28 2007-06-28 Washington University In St. Louis Multidimensional mass spectrometry or serum and celluar lipids directly from biologic extracts
US20070244076A1 (en) * 2003-10-08 2007-10-18 Musc Foundation Research Development Site and Rate Selective Prodrug Formulations of D609 with Antioxidant and Anticancer Activity
US20070270350A1 (en) 2003-12-23 2007-11-22 Musc Foundation For Research Development Methods and Compositions for the Prevention and Treatment of Inflammatory Diseases or Conditions
WO2005095955A1 (en) * 2004-03-31 2005-10-13 Children, Youth And Women's Health Service Screening for lysosomal storage disease status
EP1618876A1 (en) 2004-07-19 2006-01-25 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Use of sphingolipids for prevention and treatment of atherosclerosis
FI20041340A0 (fi) 2004-10-15 2004-10-15 Jurilab Ltd Oy Menetelmä ja testipakkaus äkillisen sydäninfarktin riskin havaitsemiseksi
US20060135497A1 (en) * 2004-12-17 2006-06-22 Ajay Gupta Combination therapy for treating heart disease
RU2428973C2 (ru) 2005-03-03 2011-09-20 Вайтал Хэлф Сайнсис Пти Лтд Составы, обладающие липидопонижающими свойствами
EP1726962A1 (en) * 2005-05-24 2006-11-29 Leiden University Medical Center Apolipoprotein E plasma levels for monitoring and reducing the risk of cardiovascular disease
DE602006021768D1 (de) * 2005-09-28 2011-06-16 Dickinson & Co Nachweis von lysophosphatidylcholin für die prognose oder diagnose eines systemischen entzündungszustands
US7972802B2 (en) 2005-10-31 2011-07-05 University Of Washington Lipoprotein-associated markers for cardiovascular disease
WO2007127192A2 (en) * 2006-04-24 2007-11-08 Duke University Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
US8137977B2 (en) * 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
CN101522910A (zh) * 2006-06-12 2009-09-02 佐拉生物科学有限公司 肌病的诊断方法
EP2029771A4 (en) * 2006-06-12 2010-08-04 Zora Biosciences Oy DIAGNOSTIC METHOD OF MYOPATHY
JP4611941B2 (ja) 2006-06-29 2011-01-12 トヨタ自動車株式会社 内燃機関の排気還流装置
DE102006034153B4 (de) 2006-07-24 2018-02-08 Magna powertrain gmbh & co kg Getriebe
JP2010500566A (ja) * 2006-08-08 2010-01-07 テシス バイオサイエンス， インコーポレイテッド 非アルコール性脂肪肝疾患（ｎａｆｌｄ）および非アルコール性脂肪性肝炎（ｎａｓｈ）のマーカーおよびその使用方法
EP2064544A1 (en) * 2006-09-14 2009-06-03 Zora Biosciences OY Biofluid metabolite profiling as a tool for early prediction of autoimmunity and type 1 diabetes risk
US8321154B2 (en) 2007-03-26 2012-11-27 Bg Medicine, Inc. Methods for detecting coronary artery disease
US20100179066A1 (en) 2007-06-07 2010-07-15 Inserm (Institut National De La Santé Et De La Rec Method for Assessing the Risk of a Cardiovascular Disease and for Diagnosing Dyslipidemia
US8026099B2 (en) * 2007-07-26 2011-09-27 Washington University Lipid profile as a biomarker for early detection of neurological disorders
WO2009132082A2 (en) * 2008-04-22 2009-10-29 Medical College Of Georgia Research Institute, Inc. Immunogenic compositions containing ceramide and methods of use thereof
US10241093B2 (en) * 2009-05-28 2019-03-26 The Cleveland Clinic Foundation Trimethylamine-containing compounds for diagnosis and prediction of disease
US9110086B2 (en) * 2009-11-27 2015-08-18 Baker Idi Heart And Diabetes Institute Holdings Limited Lipid biomarkers for stable and unstable heart disease
US9285378B2 (en) * 2010-01-29 2016-03-15 Metanomics Gmbh Means and methods for diagnosing heart failure in a subject
ES2455124T5 (es) 2010-05-05 2018-05-08 Zora Biosciences Oy Biomarcadores lipidómicos para la aterosclerosis y afección cardíaca

Also Published As

Publication number Publication date
DK2567240T4 (da) 2021-05-31
US20210003598A1 (en) 2021-01-07
WO2011138419A1 (en) 2011-11-10
EP3399318B1 (en) 2020-03-04
CN102971633B (zh) 2016-08-10
EP2385374B1 (en) 2014-01-08
US9046538B2 (en) 2015-06-02
ES2455124T5 (es) 2018-05-08
US9857386B2 (en) 2018-01-02
US12025623B2 (en) 2024-07-02
EP2385374B2 (en) 2018-02-28
US20130045217A1 (en) 2013-02-21
CA2798238A1 (en) 2011-11-10
EP2567240B2 (en) 2021-03-03
EP2567240A1 (en) 2013-03-13
US20180321266A1 (en) 2018-11-08
EP3399318A1 (en) 2018-11-07
EP2385374A1 (en) 2011-11-09
US9459264B2 (en) 2016-10-04
ES2672054T3 (es) 2018-06-12
DK2567240T3 (en) 2018-06-14
US20240385201A1 (en) 2024-11-21
EP2567240B1 (en) 2018-04-04
US20160363601A1 (en) 2016-12-15
NO2567240T3 (cg-RX-API-DMAC10.html) 2018-09-01
CA2798238C (en) 2018-01-23
US10551394B2 (en) 2020-02-04
ES2672054T5 (es) 2021-11-22
DK2385374T3 (en) 2014-03-17
CN102971633A (zh) 2013-03-13
ES2455124T3 (es) 2014-04-14
JP5871244B2 (ja) 2016-03-01
DK2385374T4 (en) 2018-04-30
US20150247873A1 (en) 2015-09-03
JP2013527449A (ja) 2013-06-27

Similar Documents

Publication Publication Date Title
BR112012019354A2 (cg-RX-API-DMAC10.html)
BR112012030039A2 (cg-RX-API-DMAC10.html)
BR112012028408A2 (cg-RX-API-DMAC10.html)
BR112012027808A2 (cg-RX-API-DMAC10.html)
BR112012025307A2 (cg-RX-API-DMAC10.html)
BR112012017960A2 (cg-RX-API-DMAC10.html)
NO2567240T3 (cg-RX-API-DMAC10.html)
BR112012002126A2 (cg-RX-API-DMAC10.html)
BR112013006400A2 (cg-RX-API-DMAC10.html)
BR112012031826A2 (cg-RX-API-DMAC10.html)
BR112012025577A2 (cg-RX-API-DMAC10.html)
BR112012023249A2 (cg-RX-API-DMAC10.html)
BR112012028186A2 (cg-RX-API-DMAC10.html)
BR112012016456A2 (cg-RX-API-DMAC10.html)
BR112012018256A2 (cg-RX-API-DMAC10.html)
BR112012025308A2 (cg-RX-API-DMAC10.html)
BR112012027945A2 (cg-RX-API-DMAC10.html)
BR112012026403A2 (cg-RX-API-DMAC10.html)
BR112012024872A2 (cg-RX-API-DMAC10.html)
BR112012023265A2 (cg-RX-API-DMAC10.html)
BR112013003284A2 (cg-RX-API-DMAC10.html)
BR112013002646A2 (cg-RX-API-DMAC10.html)
BR112012016895A2 (cg-RX-API-DMAC10.html)
BR112012028859A2 (cg-RX-API-DMAC10.html)
BR112012023446A2 (cg-RX-API-DMAC10.html)